SearchCME LoginCE Login Show Cart
NACE: National Association For Continuing Education 866-266-6223 9a am to 5 pm EST Mon-Fri
CME Course Description
   
Login to view
Course Activities.

CME Live Virtual Conferences

Go Back




Title
: Conversations in Primary Care: February 9, 2019
Activity/Course #:
: 02.09.19CPC
Cost:
: Free
Release/Start Date:
: Feb 09 2019
Expiration Date:
: Feb 09 2019
Topics:
: Primary Care Medicine
Target Audience:
: Primary Care Providers
Format:
: Live Virtual Conferences
Estimated Time To Complete CME Activity:
: 6 hours
Credit(s):
: 5.0 AMA PRA Category I Credit(s)
5.0 AANP Contact hour(s)
Hardware/Software Requirements:

There is no registration fee for this CME live virtual conference!

February 9, 2019
Broadcast Live from Ft. Lauderdale, FL
Start Time: 9:00 am EST

Program Summary:

Join Dr. Gregg Sherman and Dr. Matt Rosenberg and stay on track to fulfill your CME requirements from the comfort of your home. Utilizing an interactive, moderator led format, this program will present discussions with national thought leaders to help you hone your skills in the diagnosis and management of patients you are likely encountering in your practice. You will be able to interact with the faculty real-time to get your questions answered.

Learning Objectives:
At the conclusion of this program, participants should be able to:

  1. Recognize the risk for, and impact of hypoglycemia in patients with diabetes; Describe strategies for reducing the risk of glycemic variability; Understand effective SMBG vs. newer CGM in managing diabetes and reducing risk of dysglycemia/hypoglycemia; Differentiate between available insulin preparations and the effects on glycemic variability and hypoglycemic risk
  2. Describe the fundamentals of the pathophysiology of pulmonary arterial hypertension (PAH); Recognize the signs and symptoms indicative of PAH and identify at-risk patients using PAH-associated risk factors; Describe recommendations for diagnostic strategies to facilitate identification of PAH and referral of patients to pulmonary specialists/centers; Identify current therapies and their recommended applications in the treatment of patients with PAH
  3. Implement measurement-based tools for assessing and monitoring symptoms in patients with MDD; Individualize treatment of MDD based on patient presentation, symptom profile and side effects; Recognize when switching initial pharmacotherapy is appropriate; Incorporate shared decision-making strategies into the management of patients with MDD
  4. Recognize the pervasive nature and global impact of ADHD symptoms throughout the day; Describe the physical and psychologic morbidity and mortality associated with ADHD; Use ADHD assessment tools to aid in diagnosis, track, and measure changes in ADHD symptoms to optimize pharmacologic treatment, non-pharmacologic treatment, and symptom control throughout the day; Implement appropriate and individualized treatment regimens for patients with ADHD
  5. Describe the findings from recent trials of PCSK9i hypercholesterolemia treatments on cardiovascular outcomes; Discuss current guidelines and recommendations on the management of hyperlipidemia in high risk patients; Incorporate current data into secondary prevention treatment strategies for patients with the highest cardiovascular risk; Recognize barriers to access for PCSK9 monoclonal antibody therapy and discuss novel strategies to overcome them


Agenda*

 

9:00-9:05 AM

 

Welcome Remarks
Gregg Sherman, MD and Matt Rosenberg, MD

9:05-10:05
  Optimizing Diabetes Care: Evolving Strategies for Safer Integration of Insulin Therapy
Robert Busch, MD, FACE
Moderator Gregg Sherman, MD
10:05-10:10   Break
10:10-11:15   Pulmonary Arterial Hypertension: Importance of Early Diagnosis and Updates in Management
Charles D. Burger, MD
Moderator Matt Rosenberg, MD
11:15-11:20   Break
11:20-12:20 PM
  Case Studies in MDD: Individualizing Care
Greg Mattingly, MD
Moderator Gregg Sherman, MD
12:20-12:50

Lunch Break

12:50-1:50
  Improving Outcomes in ADHD: It Can be Done in Primary Care!
Greg Mattingly, MD
Moderator Matt Rosenberg, MD
1:50-1:55   Break
1:55-2:55
  Secondary Cardiovascular Risk Reduction: Incorporating Evolving Data to Individualize Care
Karol E. Watson, MD, PhD
Moderator Gregg Sherman, MD

2:55-3:00


Closing Remarks
Gregg Sherman, MD

* Subject to Change


Faculty
Charles D. Burger, MD
Professor of Medicine
Mayo Clinic College of Medicine
Medical Director, Pulmonary Hypertension Clinic
Mayo Clinic Florida
Jacksonville, FL

Robert S. Busch, MD, FACE
Director of Clinical Research
Albany Medical Faculty: Community Endocrine Group
Albany, NY

Greg Mattingly, MD
Associate Clinical Professor
Department of Psychiatry
Washington University School of Medicine
St. Louis, MO

Karol Watson, MD, PhD
Professor of Medicine/Cardiology
Co-director, UCLA Program in Preventive Cardiology
Director, UCLA Barbra Streisand Women's Heart Health Program
David Geffen School of Medicine at UCLA
Los Angeles, CA

Moderators
Matt T. Rosenberg, MD
Director, Mid-Michigan Health Centers
Jackson, MI

Gregg Sherman, MD

Chief Medical Officer
National Association for Continuing Education
Plantation, FL

Planning Committee
Sandy Bihlmeyer, MEd
Senior Project Manager
National Association for Continuing Education

Plantation, FL

Michelle Frisch, MPH, CHCP

Vice-President
National Association for Continuing Education

Plantation, FL

Daniela Hiedra
Activity Director
National Association for Continuing Education
Plantation, FL

Joshua F. Kilbridge
President and Creative Director
Kilbridge Associates
San Francisco, CA

Gregg Sherman, MD
Course Director
Chief Medical Officer
National Association for Continuing Education
Plantation, FL

Sponsored and Certified By
National Association for Continuing Education & Association of Black Cardiologists, Inc.
Accreditation Designation Statement
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The National Association for Continuing Education designates this live activity for a maximum of 4.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Secondary Cardiovascular Risk Reduction: Incorporating Evolving Data to Individualize Care
The Association of Black Cardiologists, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Association of Black Cardiologists, Inc. designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 5.0 contact hours of continuing education, including pharmacology hours.
Faculty Disclosure Policy
Policy on Faculty and Provider Disclosure: It is the policy of the accredited provders to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the accredited providers are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.
Commercial Support
This educational activity is supported by educational grants from Lilly USA, LLC, Takeda Pharmaceuticals U.S.A., Inc. and Lundbeck, Sanofi US and Regeneron Pharmaceuticals, and Actelion Pharmaceuticals US, Inc. This activity is also supported by educational funding provided by Amgen.